Skip to main content

Table 3 Outcome measures (n = 85)

From: Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland

Outcome measures

Week 0

Week 16

Week 52

OCS – Mean/Median

12.59 / 10,00

5.68 / 3.7

4.86 / 2.5

Range

[5.00–40.00]

[0.00–40.00]

[0.00–40.00]

p value

p = 0.000000

p = 0.000000

AQLQ -Mean/Median

2.98 / 3.10

4.27 / 4.20

4.83 / 4.8

Range

[0.0–4.9]

[1.7–7.0]

[2.5–6.9]

p value

p = 0.000000

p = 0.000000

ACQ - Mean/ Median

3.6 / 3.5

2.72 / 2.4

2.15 / 2.10

Range

[1.7–6.0]

[0.4–2.7]

[0.1–5.7]

p value

p = 0.004118

p = 0.000000

Asthma exacerbations – Mean

6.63

2.98

1.93

Range

[1.0–30.0]

[0.0–19.5]

[0.0–11.0]

p value

p = 0.000000

p = 0.000000